Associate

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Principal, PDSB, NCI, Head, Survival, Associate, Incidence, Patient, National Cancer Institute, Cancer, Doctor of Philosophy, Biotechnology, Overalls, Oncology, Neck, ICI, Clinical trial, Immune system, IL-12, ICIS, FDA, Physician, PDS, Food, Pharmaceutical industry

This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.

Key Points: 
  • This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.
  • “We have had several discussions with key opinion leaders in HNSCC regarding the use of the triple combination in HNSCC.
  • The NCI clinical trial data show significant promise in the use of PDS01ADC in combination with Versamune® HPV,” said Katharine A.
  • The event will be archived on the Investor Relations section of PDS Biotech’s website for six months.

FTI Consulting Adds Former Mexican Government Energy Official to Growing Litigation & Disputes Resolution Practice

Retrieved on: 
Wednesday, March 27, 2024
Growth, FCN, NERA, International arbitration, Associate, Strategic planning, FTI Consulting, Brattle Group, FTI, Senior, Economy, Lawsuit, Economic consulting, NERA Economic Consulting, Paulo, Economics

WASHINGTON, March 27, 2024 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Veronica Irastorza as a Senior Managing Director in the Litigation & Disputes Resolution practice within the firm’s Economic Consulting segment.

Key Points: 
  • WASHINGTON, March 27, 2024 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Veronica Irastorza as a Senior Managing Director in the Litigation & Disputes Resolution practice within the firm’s Economic Consulting segment.
  • Ms. Irastorza joins FTI Consulting with more than 20 years of experience supporting clients with issues related to competition, regulation, economics of contracts, markets, damages, valuations, disputes and arbitrations, primarily in the energy sector.
  • “As energy investment continues to grow in Latin America, political and regulatory changes in an industry that is transitioning worldwide are resulting in a growing number of disputes,” said Dr. Jose Alberro , a Senior Managing Director in the Litigation & Dispute Resolution practice and Head of International Arbitration for Latin America at FTI Consulting.
  • The team joins a growing practice of experts across Canada, the United States and Latin America led by Dr. Randal Heeb .

DP World Names Tim Gates as Vice President of Freight Forwarding for USA and Mexico

Retrieved on: 
Wednesday, March 27, 2024
Kuehne + Nagel, DP, Growth, Applied science, DP World, Transport, Associate, Southern New Hampshire University, Concordia University, Kühne

CHARLOTTE, NORTH CAROLINA, March 27, 2024 (GLOBE NEWSWIRE) -- DP World , a global leader in supply chain solutions, announces the appointment of Tim Gates as Vice President of Freight Forwarding for USA and Mexico.

Key Points: 
  • CHARLOTTE, NORTH CAROLINA, March 27, 2024 (GLOBE NEWSWIRE) -- DP World , a global leader in supply chain solutions, announces the appointment of Tim Gates as Vice President of Freight Forwarding for USA and Mexico.
  • Gates is filling the newly created role as DP World accelerates its recently announced global expansion of its freight forwarding operations.
  • Glen Clark, CEO of DP World US/Mexico, said: “Tim's appointment marks a significant step forward for our freight forwarding operations in the USA and Mexico.
  • We are thrilled to have him on board.”
    Tim Gates, VP of Freight Forwarding US/Mexico, said: “I am honored to join DP World and lead the freight forwarding division for the USA and Mexico.

Bryant University launches its first doctoral program: Doctor of Clinical Psychology (Psy.D.)

Retrieved on: 
Tuesday, March 26, 2024
Depression, Adolescence, COVID, Education, Child, Associate, Behavioural sciences, Patient, National Alliance, Bryant University, American Psychological Association, Research, Accreditation, Behavior, Anxiety, University, Faculty, Student, Psychology, Doctorate, Curriculum, Mental disorder, APA, Health informatics, School, Nursing

Smithfield, RI, March 26, 2024 (GLOBE NEWSWIRE) -- Bryant University is introducing a Doctor of Clinical Psychology (Psy.D.)

Key Points: 
  • Smithfield, RI, March 26, 2024 (GLOBE NEWSWIRE) -- Bryant University is introducing a Doctor of Clinical Psychology (Psy.D.)
  • students can opt to specialize in one of two concentrations: Child and Adolescent Psychology and Health Psychology.
  • In addition to the crucial clinical focus, a Doctoral Research Project is a core part of Bryant’s Psy.D.
  • For more information on Bryant’s new Doctor of Clinical Psychology program, visit Bryant.edu/Psyd

Monteverde & Associates PC Reminds Former RealNetworks Investors of Upcoming May 3, 2024 Deadline to Lead Federal Class Action

Retrieved on: 
Monday, March 25, 2024
Empire, Telephone, United States district court, Associate, LLP, Acquisition, Motion, Monteverde, Complaint, Supreme court, RealNetworks, Mergers and acquisitions, Book, Court, Federal

Under the terms of the Merger, each share of RealNetworks common stock owned cashed out for $0.73 per share (the “Merger Consideration”).

Key Points: 
  • Under the terms of the Merger, each share of RealNetworks common stock owned cashed out for $0.73 per share (the “Merger Consideration”).
  • Mr. Juan Monteverde is available to personally discuss this case with you, and if you wish to serve as lead plaintiff, you must seek lead appointment in the Federal Class Action no later than May 3, 2024.
  • At Monteverde & Associates PC, our firm litigates and has recovered money for shareholders… and we do it from our offices in the Empire State Building.
  • We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.

Tetricus Labs Partners with Silver Hill Hospital on Research to Advance Precision Psychiatry

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, Neurology, Mental Health, Research, Software, Artificial Intelligence, Hospitals, Science, Dow, Panic disorder, Psychiatry, Data science, Associate, Silver, Partnership, Patient, Tetricus, Bipolar disorder, Radiology, Neuroscience, Doctor of Philosophy, DSM-IV codes, Evercore, MD, Psychology, Silver Hill Hospital, Social anxiety disorder, Machine learning, Medical director, Yale University, Medicine, Nursing

Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.

Key Points: 
  • Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.
  • “We're patient-founded, patient-owned, and patient-run,” said Dow, CEO for Tetricus Labs.
  • Andrew J. Gerber, MD, PhD, President and Medical Director of Silver Hill Hospital, will join Tetricus Labs as a Medical Advisor to ensure Tetricus’ machine learning software is designed to fit within the busy workflow of hospital clinicians and staff, maximizing its accessibility for providers and potential impact on patient outcomes.
  • “This partnership represents our continued commitment to exploring innovative methods that can enhance our understanding of psychiatric disorders and improve patient outcomes."

Alliant Insurance Services Acquires Vinsa Insurance Associates, Expands California Footprint

Retrieved on: 
Tuesday, April 9, 2024
Consulting, Professional Services, State, Local, Insurance, Public Policy, Government, Partnership, P&C, Associate, Organization, High, Alliant, Financial services

Alliant Insurance Services has acquired Vinsa Insurance Associates within its Alliant Public Entity division, expanding its footprint in California.

Key Points: 
  • Alliant Insurance Services has acquired Vinsa Insurance Associates within its Alliant Public Entity division, expanding its footprint in California.
  • Based in Lancaster, California, Vinsa is an independent P&C insurance agency that specializes in providing customized and comprehensive insurance coverage solutions for commercial and personal lines, with a focus on serving public entity organizations.
  • Vinsa works with many of the highest-rated insurance carriers, aiding clients in securing the right company and coverage for their unique insurance requirements.
  • Vinsa Insurance Associates is currently operating as Vinsa from its headquarters in Lancaster, California.

Cadmus Awarded $27 Million Contract to Launch U.S. Department of Transportation Reconnecting Communities Institute

Retrieved on: 
Tuesday, April 9, 2024
Public Transport, Other Transport, Consulting, Transport, Professional Services, Public Policy, Government, Business, White House, Federal Government, State, Local, Other Professional Services, RCN, DOT, Employment, Learning, Health, Data analysis, Partnership, Education, Associate, Private sector, Engineering, Investment, Center for Neighborhood Technology, RCI, Renewable energy

Cadmus, a leading provider of technical and strategic expertise to governments, energy utilities, and private sector companies worldwide, has been awarded up to $27 million to establish and administer the U.S. Department of Transportation’s (DOT) Reconnecting Communities Institute (RCI).

Key Points: 
  • Cadmus, a leading provider of technical and strategic expertise to governments, energy utilities, and private sector companies worldwide, has been awarded up to $27 million to establish and administer the U.S. Department of Transportation’s (DOT) Reconnecting Communities Institute (RCI).
  • The contract, managed by the Build America Bureau (Bureau), underscores Cadmus' extensive experience in delivering place-based technical assistance and transportation solutions to federal, state, and local government clients.
  • Under this contract, the RCI will serve as the Bureau’s center for learning and capacity building, empowering communities to develop and execute reconnection projects.
  • With the recent contract award, Cadmus and its partners are working to rapidly stand up the RCI, which will fully launch later this year.

AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at AACR 2024

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Survival, Survival rate, NSCLC, Associate, Cervical cancer, Medicine, Patient, Lung, University, MD, Lung cancer, AACR, University of Southern California, Vaccine

The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.

Key Points: 
  • The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.
  • Affinity tuned AIC100 is expected to selectively bind and kill tumor cells expressing cell surface ICAM-1 while sparing healthy cells.
  • “We are excited to share preclinical proof-of-concept data for our affinity-tuned CAR T program AIC100 in new solid tumor types.
  • “This promising preclinical data presented at AACR 2024 suggest that AIC100 could be a potential new option for patients with these ICAM-1-positive tumors.”

PanTher Therapeutics Presents Positive First-in-Human Data for PTM-101 in Pancreatic Cancer at AACR Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Toxicity, Infection, Associate, Patient, Cancer, Doctor of Philosophy, MD, Panther, AACR, Pancreatic cancer, Neoplasm, Clinical trial, Therapy, Paclitaxel, Pancreas, Pancreatitis, Safety, Monash University, Prognosis, Pharmaceutical industry

PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.

Key Points: 
  • PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
  • Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
  • Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
  • Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.